Born in London as the only daughter of the eminent jurist,
Tom Bingham (
later Lord Bingham of Cornhill,
KG), and Elizabeth
née Loxley, Kate Bingham was educated at
St Paul's Girls' School, London,
[3] before going up to
Christ Church, Oxford, where she graduated with a
first-class degree in
Biochemistry (
MA).
[4]
Bingham then pursued further studies at
Harvard Business School, taking the
degree of
MBA.
[5]
Bingham worked in business development for
Vertex Pharmaceuticals and consultants
Monitor Company before joining
Schroder Ventures in 1991 (
now SV Health Investments).
[6][7] She became a managing partner specializing in
biotechnology, and has served on the
boards of companies in the UK, US, Ireland, Sweden and Germany, including Autifony Therapeutics, Bicycle Therapeutics, Mestag Therapeutics,
Pulmocide, Sitryx, and Zarodex Therapeutics.
[7][8]
As of January 2021 she is listed as being a director of the following active companies:
[2] Mestag Therapeutics Ltd; Cybele Therapeutics Ltd; Bicycle tx Ltd; Bicycle Therapeutics plc; Sitryx Therapeutics Ltd; Pulmocide Ltd; Autofony Therapeutics Ltd; Bicycle RD Ltd; SV Health Investors Ltd (whose subsidiaries include the Dementia Discovery Fund);
[9] and SCV Health Managers LLP.
Bingham also serves as a
Trustee of the
Francis Crick Institute.
[6]
